Sodium Valproate Tablets IP

1. Product Introduction

Sodium Valproate is a broad-spectrum antiseizure medicine used in the management of several types of epilepsy. The supplied product range consists of 200 mg, 300 mg and 500 mg IP enteric-coated (gastro-resistant) tablets. Healthy Life Pharma Pvt. Ltd. is identified as manufacturer and Healthy Inc as exporter in the supplied product description.

Third-party manufacturing and export enquiries may cover formulation documentation, approved markets, quality specifications and packaging options. Facility certification, manufacturing processes and regulatory approvals must be confirmed from current documents.

Safety: Valproate carries major pregnancy and reproductive risks and should be prescribed only under applicable specialist and regulatory safeguards.

2. Product Specifications

3. Manufacturing and Formulation Considerations

Sodium valproate is moisture-sensitive. Appropriate formulation development considers controlled humidity, blend uniformity, tablet strength, coating integrity and validated packaging barriers. Enteric coatings are intended to delay release until after gastric transit.

Important formulation distinction: Gastro-resistant tablets and prolonged-release (Chrono/CR) tablets have different release characteristics and are not interchangeable without prescriber review. The supplied compositions confirm only gastro-resistant tablets; prolonged-release manufacturing is not verified.

4. Quality Assurance

Relevant batch quality testing may include identification, assay, dosage-unit uniformity, related substances, dissolution/disintegration using the applicable gastro-resistant method, and stability testing. Acceptance criteria must follow the current approved IP monograph and registered specification rather than generic fixed percentages.

For supply evaluation, request a batch-specific Certificate of Analysis, stability evidence and current manufacturing/quality certificates.

5. Mechanism and Therapeutic Uses

Sodium valproate has several antiseizure actions, including enhancement of inhibitory GABA signalling and effects on neuronal ion channels. It is used for certain generalized and focal seizure disorders as directed by a neurologist.

Valproate is also used for certain bipolar disorder indications and migraine prevention in some markets and formulations, but approvals and restrictions differ. These uses must not be assumed to apply to every gastro-resistant product. It is not an antihypertensive or cardiac medicine.

Pregnancy and reproductive risk: Exposure during pregnancy can cause major congenital malformations and long-term neurodevelopmental harm. Many jurisdictions impose strict pregnancy-prevention programmes and restrictions, including for patients who can father children.

6. Export and Regulatory Support

Healthy Inc is named as exporter in the supplied material. B2B partners should request product-specific registration status, CTD/ACTD documentation where available, current GMP evidence, Certificate of Pharmaceutical Product, Free Sale Certificate and Certificate of Analysis as applicable.

WHO-GMP status, Star Export House designation, destination-market approvals, shipping terms and the claimed manufacturing location require documentary confirmation before publication as verified claims.

7. Frequently Asked Questions

Q: Which strengths are included?
A: The supplied IP compositions specify 200 mg, 300 mg and 500 mg gastro-resistant tablets.

Q: Are these the same as Chrono/CR tablets?
A: No. Enteric coating delays release in the stomach; prolonged-release technology controls drug release over time. Do not switch formulations without medical advice.

Q: Is sodium valproate safe during pregnancy?
A: It carries substantial fetal risks and is highly restricted. Patients who are pregnant, planning pregnancy or may become pregnant need urgent specialist advice; they should not abruptly stop antiseizure therapy on their own.

Q: Can the tablets be crushed?
A: No. Swallow gastro-resistant tablets whole unless the specific approved product instructions say otherwise.

8. Dosage and Administration

Dosage is individualized according to the indication, age, body weight, clinical response, concomitant medicines and local prescribing information. Treatment is usually started at a lower dose and adjusted by the prescriber. No universal dosing schedule should be inferred from the strengths listed on this page.

Swallow enteric-coated tablets whole with water; do not chew or crush. Food instructions and dose frequency should follow the approved leaflet. Do not stop valproate suddenly because seizures may recur or worsen.

9. Side Effects and Precautions

Possible adverse effects include nausea, tremor, sleepiness, weight gain, hair changes and thrombocytopenia. Serious risks include liver injury, pancreatitis, hyperammonaemia/encephalopathy and blood disorders. Liver function, blood counts and other monitoring may be needed as directed by the prescriber.

Pregnancy warning: Valproate may cause severe birth defects and developmental disorders; restrictions apply before and during pregnancy. Patients should receive current country-specific counselling and risk-prevention materials. Never stop prescribed seizure medication abruptly without urgent medical guidance.

Important interactions include other antiepileptics (notably lamotrigine), carbapenem antibiotics and medicines affecting bleeding. Seek urgent care for severe abdominal pain, persistent vomiting, jaundice, unusual bruising or worsening consciousness.

10. Storage Instructions

Store in the original tightly closed, moisture-protective packaging according to the approved product label. Protect from excessive heat and humidity; keep out of reach of children. The proposed “below 25°C” condition and a 36-month shelf life must be confirmed using product-specific stability and registration records.